PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study [PDF]
PeerJ, 2022 Background The Kidney Disease Improving Global Outcomes (KDIGO) 2021 guidelines recommend Rituximab (RTX) as the first-line therapy and phospholipase A2 receptor (PLA2R) antibody as a biomarker for remission and prognosis in patients with idiopathic ...
Yiqing Huang +13 more
doaj +2 more sources
Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody [PDF]
PeerJ, 2020 Background To discuss the clinicopathological features and prognosis of patients with idiopathic membranous nephropathy (IMN) who are serum-negative for the anti-PLA2R antibody.
Wenkai Guo +6 more
doaj +2 more sources
Phospholipase A2 receptor (PLA2R) related membranous nephropathy - not specific for idiopathic cases any more [PDF]
Journal of Nephropathology, 2018 Context: Membranous nephropathy is among the most common causes of nephrotic syndrome in adults. Evidence Acquisitions: PubMed, EBSCO, Web of Science, directory of open access journals (DOAJ), EMBASE, and Google Scholar with keywords of phospholipase A2 ...
Bahar Bastani
doaj +1 more source
Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. [PDF]
PLoS ONE, 2017 INTRODUCTION:Clinical course of membranous nephropathy (MN) is difficult to predict. Measurement of circulating anti-PLA2R autoantibodies (PLA2R-Ab) and detection in immune deposits of PLA2R antigen (PLA2R-Ag) are major advances in disease understanding.
Franck Pourcine +6 more
doaj +1 more source
PLoS ONE, 2020 Background Primary membranous nephritis (PMN) is an autoimmune disease induced by the deposit of antibodies (Ab) to the phospholipase receptor A2 receptor (PLA2R) on podocytes.
Tarak Dhaouadi +10 more
doaj +2 more sources
Renal Phospholipase A2 Receptor and the Clinical Features of Idiopathic Membranous Nephropathy
Chinese Medical Journal, 2017 Background: According to the renal phospholipase A2 receptor (PLA2R) immunohistochemistry, idiopathic membranous nephropathy (iMN) could be categorized into PLA2R-associated and non-PLA2R-associated iMN. This study aimed to examine whether the non-PLA2R-
Ning-Xin Xu +8 more
doaj +1 more source
Diagnostics, 2022 Primary membranous nephropathy (MN) is caused by antibodies against podocyte antigens, especially the type M receptor of phospholipase A2 (PLA2R) and thrombospondin type-1 domain containing 7 A (THSD7A).
Ligia C. Battaini +8 more
doaj +1 more source
Nefrología Latinoamericana, 2021 Antecedentes: En fecha reciente se propuso utilizar el ac-PLA2R en el diagnóstico y seguimiento de la nefropatía membranosa idiopática (NMI). Objetivo: Evaluar el rendimiento de los ac-PLA2R durante el inicio, la remisión y la recaída en los primeros ...
Sofía San Román +4 more
doaj +1 more source
Profile of Indian Patients With Membranous Nephropathy
Kidney International Reports, 2020 Introduction: The majority of primary membranous nephropathy (MN) cases are no longer considered idiopathic with the discovery of the podocytic autoantigens: phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain–containing 7A (THSD7A ...
Priyadarsani Subramanian +8 more
doaj +1 more source
Saudi Journal of Kidney Diseases and Transplantation, 2023 Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome (NS) in nondiabetic adults, with about 70%–80% of cases of MN being primary MN (pMN). Many studies have shown that serum phospholipase A2 receptor (PLA2R) antibodies are a
Deepesh Vellakampadi +3 more
doaj +1 more source